Back to Bills
HOUSE-BILL 946119th Congress

HOUSE-BILL 946: H.R.946 - ORPHAN Cures Act

Introduced: February 4, 2025
Status: Introduced
supported

AI-Powered Summary

Generated by AI Analysis

HOUSE-BILL 946, titled the 'ORPHAN Cures Act', aims to amend the Drug Price Negotiation Program by expanding the exclusion criteria for orphan drugs, which are essential for individuals with rare diseases. The legislation addresses major themes such as healthcare access, pharmaceutical pricing, and the balance between innovation and affordability. Key provisions include a clarification of orphan drug definitions to encompass those for one or more rare diseases, and adjustments to the drug approval timeline calculations that may facilitate more orphan drugs entering the negotiation process. Implementation of these changes is expected to enhance access to necessary treatments for affected individuals, though there are concerns about potential increases in drug prices that could disproportionately impact low-income populations. Overall, the bill seeks to improve the availability and affordability of critical medications while navigating the complexities of healthcare rights and pharmaceutical market dynamics.

Demographic Impact Analysis

AI Demographics Analysis

Summary

Overall Constitutional Implications

HOUSE-BILL 946 aims to enhance access to orphan drugs, which could improve health outcomes for individuals with rare diseases. However, the potential for unequal access based on demographic factors introduces ambiguity regarding its constitutional alignment.

Key Individual Rights Affected

Positive

  • Right to Health Care Access
  • Equal Protection under the Law

Negative

  • Potential Disparities in Access
  • Impact on Future Drug Development

Constitutional Provisions

  • 14th Amendment - Equal Protection Clause
  • Commerce Clause

Potential Constitutional Challenges

  • Disparities in access to medications for marginalized groups could lead to equal protection challenges.
  • Concerns regarding the bill's impact on pharmaceutical innovation may raise questions about the right to health care access.

Summary

While HOUSE-BILL 946 seeks to improve access to orphan drugs, its implications for individual rights, particularly regarding equal protection and health care access, are complex and may require further scrutiny to ensure that it does not disproportionately disadvantage vulnerable populations.

Constitutional Analysis

supported

This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.

Analysis generated using AI-powered review of constitutional principles and legal precedents.

Take Action

Text 50409

💡 How to use:

These links will start a conversation with ResistBot. When prompted, mention H.R. 946 to reference this bill.

Contact Your Representatives

Write to YOUR elected officials about this bill

Rate This Bill

Sign in to save a private rating for this bill and track your civic engagement over time.

Sign In Free

Policy Topics

Timeline

February 4, 2025

Bill Introduced

Current

Introduced

June 12, 2026

Last Updated

Ask the Constitutional AI About This Bill

Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.

Sign In Free to Chat